media – Page 644 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Aspect Imaging’s neonatal MRI device gains FDA clearance

Aspect Imaging has secured 510(k) clearance for the commercialisation of its neonatal brain and head magnetic resonance imaging (MRI) device from the US Food and Drug Administration (FDA).
- Source: Medicaldevice
- 506
- July 24, 2017
Aspect Imaging Company Insight FDA MRI
NovellusDx to use Gene Editing Institute’s technology for cancer diagnostics

Israel-based NovellusDx has established a genomic cancer research partnership with Christiana Care Health System's Gene Editing Institute to speed-up the development of treatments for the disease.
- Source: Medicaldevice
- 471
- July 24, 2017
cancer Company Insight NovellusDx
US researchers say blood test can detect Alzheimer’s early

Researchers at Washington University School of Medicine in St Louis, US, have carried out a study to identify a rapid and inexpensive test for Alzheimer’s disease.
- Source: Medical devices
- 448
- July 21, 2017
Alzheimer's Researches
Tentative US approval for Merck’s diabetes therapy

The US Food and Drug Administration has given a tentative green light to Merck & Co’s follow-on biologic basal insulin Lusduna Nexvue.
- Source: pharmatimes
- 474
- July 21, 2017
Company Insight diabetes Lusduna Nexvue Market Views
Sanofi, Ablynx sign $2.7bn research, licensing pact

Sanofi has signed a research pact and licensing deal with Ablynx that could bring as much as $2.7 billion euros to the Belgian biotech’s coffers if all targets are met.
- Source: pharmatimes
- 500
- July 21, 2017
Company Insight Market Views Sanofi Ablynx
NICE u-turn backs use of Teva’s asthma biologic

The National Institute for Health and Care Excellence (NICE) is now backing routine NHS commissioning of Teva’s Cinqaero to treat a severe form of asthma after having initially been minded to block the drug’s use.
- Source: pharmatimes
- 466
- July 21, 2017
asthma New Approvals NICE
EU nod for Gedeon’s novel antipsychotic Reagila

European regulators have approved Gedeon Richter’s novel antipsychotic Reagila as a new option for the treatment of patients with schizophrenia.
- Source: pharmatimes
- 476
- July 20, 2017
New Approvals Reagila schizophrenia
ABPI seeks to challenge NICE reforms in court

The Association of the British Pharmaceutical Industry is seeking to challenge in court new rules on appraising medicines for NHS use, insisting that the changes will hinder patient access to the latest medical innovations.
- Source: pharmatimes
- 799
- July 20, 2017
innovation Policy
Drugdu.com (Ddu) to Attend India Medicall Expanding the Indian Market

The 17th Indian Premier B2B Medical Equipment Show (Medicall 2017) will be held in Chennai, the fourth largest city in India, from July 28 to July 30, 2017. As the leading global pharmaceuticals and medical devices B2B online platform, Ddu is going to focus on showcasing their online-to-offline promotional exhibition method along with the products of high priority members in India.
- Source: Ddu
- 542
- July 18, 2017
Exhibitions & Activities medical device Medicall
Ddu Wins High Praise at Shanghai CEEP

The Shanghai International Clinical Examination Equipment and Products Exhibition 2017 (CEEP) was held at the Shanghai World Expo Exhibition and Convention Center from July 13 to July 15, 2017. Ddu, the leading global pharmaceuticals and medical devices B2B online platform, attended Shanghai CEEP with products of high priority members and publically presented the Ddu app, receiving high praise.
- Source: Ddu
- 658
- July 17, 2017
CEEP Exhibitions & Activities medical device

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.